Drug Database
Back to search

Belgium· BE-AMP-SAM660798-00

Rivaroxaban EG 2.5 mg

A rivaroxaban product containing rivaroxaban, registered in Belgium by EG. The same ATC class is registered in 15 of our 19 countries.

ATC B01AF01

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedRivaroxaban EG 2.5 mgATCB01AF01REGISTER NO.BE-AMP-SAM660798-00PACKS LISTED3CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about rivaroxabanAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Rivaroxaban is registered in 15 of 19 countries.

Countries holding a registration under ATC B01AF01 (rivaroxaban), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose
Search rivaroxaban products by name

Rivaroxaban · ATC B01AF01

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rivaroxaban costs, country by country.

Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.67 in France to $5.20 in United States — a ×7.7 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Rivaroxaban · price per daily dose (20 mg)

USD · FX 28 Sept 2026

  • US United States$5.20 (acquisition cost)
  • CH Switzerland$2.66
  • IT Italy$1.08
  • FR France$0.67
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Rivaroxaban
Manufacturer
EG
Country
Belgium (BE)
ATC code
B01AF01
ATC class
Rivaroxaban
Defined daily dose
20 mg, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 3

2 priced
  • be_apb
    4791489
    EUR 29.36
  • be_apb
    4791497
    EUR 82.95
  • be_apb
    7739485

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

391 interactions on record for rivaroxaban.

Graded by severity as the source publishes them — 134 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check rivaroxaban against other medicinesHow interaction checks work

Rivaroxaban · interactions on record

391 records

  • 134 severe
  • 213 moderate
  • 2 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe

42 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under B01AF01

Rivaroxaban, as other registers publish it.

All rivaroxaban products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e215ed97-f9f1-4466-8ce4-fd985b8fae1a
GET /v1/drugs/e215ed97-f9f1-4466-8ce4-fd985b8fae1a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Rivaroxaban EG 2.5 mg",
  "name_fr": "Rivaroxaban EG 2.5 mg",
  "name_nl": "Rivaroxaban EG 2.5 mg",
  "amp_code": "SAM660798-00",
  "strengths": [
    "2.5000",
    "58.0300",
    "0.6700"
  ],
  "pack_count": 26,
  "substances": [
    "Rivaroxaban",
    "Lactose Monohydrate",
    "Sodium Laurilsulfate"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Rivaroxaban",
  "authorisation_numbers": [
    "BE660798"
  ]
}
API referenceMCP serverPlans

See everything about rivaroxaban.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console